Overview

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Status:
RECRUITING
Trial end date:
2030-01-23
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered in the neoadjuvant setting followed by radical prostatectomy and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered in the neoadjuvant setting.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen